Drug Trial Radar · NCT02455622
Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age
Last checked: Nov 20, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Oct 28, 2015
Primary completion
Jul 29, 2025
Study completion Jul 29, 2025
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Takeda Development Center Americas, Inc.
- First posted
- May 28, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, up to 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This long-term study will provide Elaprase treatment to children enrolled in this study and will utilize data from both enrolled patients and Hunter Outcome Survey (HOS) patient registry data to conduct the primary growth analysis to assess changes in height and weight in patients with Mucopolysaccharidosis II (Hunter syndrome) MPS II.
Conditions
- Hunter Syndrome
Interventions
Elaprase for intravenous (IV) infusionDrug
Patients enrolled in this study will receive once-weekly IV infusions of Elaprase at a dose of 0.5 mg/kg and will be followed for a minimum of 5 years after initiation of Elaprase treatment, or until they reach their 10th birthday, whichever is longer.Height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Height OverallTime frame: Prospective participants: From Baseline through End-of-Study (approximately 9.75 years); HOS participants followed up to a maximum of 9.5 years where participant data were accessed from the registry between the period of 08/01/07 to 02/06/22
- Weight OverallTime frame: Prospective participants: From Baseline through End-of-Study (approximately 9.75 years); HOS participants followed up to a maximum of 9.5 years where participant data were accessed from the registry between the period of 08/01/07 to 02/06/22
- Change From Baseline in Height Measured by Z-scoreTime frame: Prospective participants: From Baseline through End-of-Study (approximately 9.75 years); HOS participants followed up to a maximum of 9.5 years where participant data were accessed from the registry between the period of 08/01/07 to 02/06/22
- Change From Baseline in Weight Measured by Z-scoreTime frame: Prospective participants: From Baseline through End-of-Study (approximately 9.75 years); HOS participants followed up to a maximum of 9.5 years where participant data were accessed from the registry between the period of 08/01/07 to 02/06/22
- Number of Participants With Clinical Significant Abnormal Neurological ExaminationTime frame: From Screening to End-of-Study (approximately 9.75 years)
- Number of Participants With Treatment-emergent Adverse Events (TEAE)Time frame: From screening to End-of-Study (approximately 9.75 years)
- Number of Participants With Clinically Significant Abnormal Urinalysis ValuesTime frame: From screening to End-of-Study (approximately 9.75 years)
- Number of Participants With Clinically Significant Abnormal Serum Chemistry ValuesTime frame: From screening to End-of-Study (approximately 9.75 years)
- Number of Participants With Clinically Significant Abnormal Hematology ValuesTime frame: From screening to End-of-Study (approximately 9.75 years)
Locations
8 sites in 8 countries. Site status is shown where the registry gives one.
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Hospital Infantil Dr Robert Reid Cabral
Santo Domingo, Dominican Republic
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Germany
Hospital Kuala Lumpur
Kuala Lumpur, Malaysia
Philippine General Hospital
Manila, Philippines
Mother and Child Health Care Institute of Serbia Dr Vukan Cupic
Belgrade, Serbia
Chulalongkorn University
Bangkok, Thailand
National Pediatrics Hospital
Hanoi, Vietnam
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.